(Q50986703)

English

Concurrent chemoradiotherapy plus adjuvant chemotherapy versus concurrent chemoradiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma: a phase 3 multicentre randomised controlled trial.

scientific article published on 7 December 2011

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

26 March 2018

http://europepmc.org/abstract/MED/22154591

Concurrent chemoradiotherapy plus adjuvant chemotherapy versus concurrent chemoradiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma: a phase 3 multicentre randomised controlled trial. (English)

1 reference

Europe PubMed Central

PubMed publication ID

26 March 2018

http://europepmc.org/abstract/MED/22154591

chemoradiotherapy

0 references

phase III clinical trial

0 references

multicenter clinical trial

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

23

1 reference

Europe PubMed Central

PubMed publication ID

26 March 2018

http://europepmc.org/abstract/MED/22154591

20

object named as

Ling-Long Tang

1 reference

Europe PubMed Central

PubMed publication ID

26 March 2018

author name string

Lei Chen

1

1 reference

Europe PubMed Central

PubMed publication ID

26 March 2018

http://europepmc.org/abstract/MED/22154591

Chao-Su Hu

2

1 reference

Europe PubMed Central

PubMed publication ID

26 March 2018

http://europepmc.org/abstract/MED/22154591

Xiao-Zhong Chen

3

1 reference

Europe PubMed Central

PubMed publication ID

26 March 2018

http://europepmc.org/abstract/MED/22154591

Guo-Qing Hu

4

1 reference

Europe PubMed Central

PubMed publication ID

26 March 2018

http://europepmc.org/abstract/MED/22154591

Zhi-Bin Cheng

5

1 reference

Europe PubMed Central

PubMed publication ID

26 March 2018

http://europepmc.org/abstract/MED/22154591

Yan Sun

6

1 reference

Europe PubMed Central

PubMed publication ID

26 March 2018

http://europepmc.org/abstract/MED/22154591

Wei-Xiong Li

7

1 reference

Europe PubMed Central

PubMed publication ID

26 March 2018

http://europepmc.org/abstract/MED/22154591

Yuan-Yuan Chen

8

1 reference

Europe PubMed Central

PubMed publication ID

26 March 2018

http://europepmc.org/abstract/MED/22154591

Fang-Yun Xie

9

1 reference

Europe PubMed Central

PubMed publication ID

26 March 2018

http://europepmc.org/abstract/MED/22154591

Shao-Bo Liang

10

1 reference

Europe PubMed Central

PubMed publication ID

26 March 2018

http://europepmc.org/abstract/MED/22154591

Yong Chen

11

1 reference

Europe PubMed Central

PubMed publication ID

26 March 2018

http://europepmc.org/abstract/MED/22154591

Ting-Ting Xu

12

1 reference

Europe PubMed Central

PubMed publication ID

26 March 2018

http://europepmc.org/abstract/MED/22154591

Bin Li

13

1 reference

Europe PubMed Central

PubMed publication ID

26 March 2018

http://europepmc.org/abstract/MED/22154591

Guo-Xian Long

14

1 reference

Europe PubMed Central

PubMed publication ID

26 March 2018

http://europepmc.org/abstract/MED/22154591

Si-Yang Wang

15

1 reference

Europe PubMed Central

PubMed publication ID

26 March 2018

http://europepmc.org/abstract/MED/22154591

Bao-Min Zheng

16

1 reference

Europe PubMed Central

PubMed publication ID

26 March 2018

http://europepmc.org/abstract/MED/22154591

Ying Guo

17

1 reference

Europe PubMed Central

PubMed publication ID

26 March 2018

http://europepmc.org/abstract/MED/22154591

Ying Sun

18

1 reference

Europe PubMed Central

PubMed publication ID

26 March 2018

http://europepmc.org/abstract/MED/22154591

Yan-Ping Mao

19

1 reference

Europe PubMed Central

PubMed publication ID

26 March 2018

http://europepmc.org/abstract/MED/22154591

Yu-Ming Chen

21

1 reference

Europe PubMed Central

PubMed publication ID

26 March 2018

http://europepmc.org/abstract/MED/22154591

Meng-Zhong Liu

22

1 reference

Europe PubMed Central

PubMed publication ID

26 March 2018

http://europepmc.org/abstract/MED/22154591

publication date

7 December 2011

1 reference

Europe PubMed Central

PubMed publication ID

26 March 2018

http://europepmc.org/abstract/MED/22154591

Lancet Oncology Commission

1 reference

Europe PubMed Central

PubMed publication ID

26 March 2018

http://europepmc.org/abstract/MED/22154591

13

1 reference

Europe PubMed Central

PubMed publication ID

26 March 2018

http://europepmc.org/abstract/MED/22154591

2

1 reference

Europe PubMed Central

PubMed publication ID

26 March 2018

http://europepmc.org/abstract/MED/22154591

163-171

1 reference

Europe PubMed Central

PubMed publication ID

26 March 2018

http://europepmc.org/abstract/MED/22154591

Global cancer statistics

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970320-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Nasopharyngeal carcinoma treated by radical radiotherapy alone: Ten-year experience of a single institution

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970320-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Re-evaluation of 6th edition of AJCC staging system for nasopharyngeal carcinoma and proposed improvement based on magnetic resonance imaging

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970320-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized Intergroup study 0099

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970320-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomized trial of radiotherapy versus concurrent chemoradiotherapy followed by adjuvant chemotherapy in patients with American Joint Committee on Cancer/International Union against cancer stage III and IV nasopharyngeal cancer of the endemic varie

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970320-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomized trial of radiotherapy plus concurrent-adjuvant chemotherapy vs radiotherapy alone for regionally advanced nasopharyngeal carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970320-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Preliminary results of a prospective randomized trial comparing concurrent chemoradiotherapy plus adjuvant chemotherapy with radiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma in endemic regions of china

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970320-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Concurrent Chemotherapy-Radiotherapy Compared With Radiotherapy Alone in Locoregionally Advanced Nasopharyngeal Carcinoma: Progression-Free Survival Analysis of a Phase III Randomized Trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970320-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Overall Survival After Concurrent Cisplatin-Radiotherapy Compared With Radiotherapy Alone in Locoregionally Advanced Nasopharyngeal Carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970320-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase III study of concurrent chemoradiotherapy versus radiotherapy alone for advanced nasopharyngeal carcinoma: positive effect on overall and progression-free survival

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970320-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase III study comparing standard radiotherapy with or without weekly oxaliplatin in treatment of locoregionally advanced nasopharyngeal carcinoma: preliminary results

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970320-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Adjuvant chemotherapy with vincristine, cyclophosphamide, and doxorubicin after radiotherapy in local-regional nasopharyngeal cancer: results of a 4-year multicenter randomized study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970320-5

7 January 2021

based on heuristic

inferred from DOI database lookup

A phase III study of adjuvant chemotherapy in advanced nasopharyngeal carcinoma patients

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970320-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Concurrent and adjuvant chemotherapy for nasopharyngeal carcinoma: a factorial study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970320-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Chemotherapy in locally advanced nasopharyngeal carcinoma: an individual patient data meta-analysis of eight randomized trials and 1753 patients.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970320-5

7 January 2021

based on heuristic

inferred from DOI database lookup

The additional value of chemotherapy to radiotherapy in locally advanced nasopharyngeal carcinoma: a meta-analysis of the published literature

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970320-5

7 January 2021

based on heuristic

inferred from DOI database lookup

How does intensity-modulated radiotherapy versus conventional two-dimensional radiotherapy influence the treatment results in nasopharyngeal carcinoma patients?

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970320-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Improved complete response rate and survival in advanced head and neck cancer after three-course induction therapy with 120-hour 5-FU infusion and cisplatin.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970320-5

7 January 2021

based on heuristic

inferred from DOI database lookup

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970320-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC)

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970320-5

7 January 2021

based on heuristic

inferred from DOI database lookup

A phase III randomized study comparing cisplatin and fluorouracil as single agents and in combination for advanced squamous cell carcinoma of the head and neck

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970320-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomized phase II trial of concurrent cisplatin-radiotherapy with or without neoadjuvant docetaxel and cisplatin in advanced nasopharyngeal carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970320-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Paclitaxel, carboplatin, and gemcitabine in metastatic nasopharyngeal carcinoma: a Phase II trial using a triplet combination.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970320-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Another way to estimate outcome of advanced nasopharyngeal carcinoma--is concurrent chemoradiotherapy adequate?

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970320-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Improvement of survival after addition of induction chemotherapy to radiotherapy in patients with early-stage nasopharyngeal carcinoma: Subgroup analysis of two Phase III trials

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970320-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Quantification of plasma Epstein-Barr virus DNA in patients with advanced nasopharyngeal carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970320-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S1470-2045(11)70320-5

1 reference

Europe PubMed Central

PubMed publication ID

26 March 2018

http://europepmc.org/abstract/MED/22154591

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

26 March 2018

http://europepmc.org/abstract/MED/22154591

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q50986703&oldid=1417661527"